Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review Publisher



Kianfar N1 ; Dasdar S1 ; Mahmoudi H1 ; Daneshpazhooh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Women's Dermatology Published:2022


Abstract

Pemphigus vulgaris is a chronic autoimmune mucocutaneous blistering disorder. Apart from the disease itself, other aspects of patients life, including psychological, social, and financial, can be affected. Women are particularly more disposed to the impact of the disease due to their physiological characteristics, the specific periods of pregnancy and lactation as well as their social and familial role. In this review, we summarized the burden of pemphigus vulgaris on various aspects of women s lives. It is essential to understand these problems and provide appropriate support for patients with such a burdensome disease. © 2022 Elsevier Inc. All rights reserved.
Related Docs
View other Related Docs
1. Autoimmune Bullous Disease Quality of Life (Abqol) Questionnaire: Validation of the Translated Persian Version in Pemphigus Vulgaris, International Journal of Women's Dermatology (2020)
2. Bullous Pemphigoid, Nature Reviews Disease Primers (2025)
3. Assessing Quality of Life in Patients With Autoimmune Bullous Diseases Using the Persian Version of Treatment of Autoimmune Bullous Disease Quality of Life Questionnaire Finds Similar Effects in Women As Men, International Journal of Women's Dermatology (2022)
4. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
5. Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy, International Journal of Women's Dermatology (2022)
6. Illness Perception of Patients With Pemphigus Vulgaris, International Journal of Women's Dermatology (2019)
7. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
8. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (43)
Kamran Balighi (30)
Other Related Docs
9. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
10. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)
11. Rituximab Treatment and Improvement of Health-Related Quality of Life in Patients With Pemphigus, Cutis (2023)
12. Family Impact of Pemphigus Disease in an Iranian Population Using the Family Dermatology Life Quality Index, International Journal of Women's Dermatology (2020)
13. Management of Pemphigus Disease in Pregnancy, American Journal of Reproductive Immunology (2017)
14. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)
15. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
16. Retrospective Study of Gingival Involvement in Pemphigus: A Difficult to Treat Phenomenon, Dermatologic Therapy (2022)
17. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
18. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)
19. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)
20. What Is Novel in the Clinical Management of Pemphigus Vulgaris?, Expert Review of Clinical Pharmacology (2024)
21. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
22. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
23. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
24. Interleukin 4 Inhibition As a Potential Therapeutic in Pemphigus, Cytokine (2016)
25. Evaluation of Autoimmune Bullous Diseases in Elderly Patients in Iran: A 10-Year Retrospective Study, SKINmed (2017)
26. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
27. “Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study, Dermatologic Therapy (2019)
28. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
29. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus, Oral Diseases (2023)
30. The Study of Psychiatric Comorbidity in Patient With Pemphigus, Tehran University Medical Journal (2016)
31. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
32. Pemphigus Vulgaris, Mayo Clinic Proceedings (2024)
33. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
34. Anti-Desmoglein-1 Levels As Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab, Dermatologic Therapy (2018)
35. Adverse Electrocardiographic Effects of Rituximab Infusion in Pemphigus Patients, Dermatologic Therapy (2020)
36. Covid-19 in Pemphigus Vulgaris Patients With Previous Rituximab Therapy: A Tele-Medicine Experience, Journal of Dermatological Treatment (2020)
37. Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic, Journal of the American Academy of Dermatology (2020)
38. Correlation Between Serum Cardiac Troponin I Level and Pdai Score in Patients With Pemphigus Vulgaris, Archives of Dermatological Research (2024)
39. Factors Associated With the Healing Time of Pemphigus Vulgaris Oral Lesions: A Prospective Study, Oral Diseases (2023)
40. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
41. Persistent Nasal Skin Lesions in Pemphigus Patients and the Role of Methotrexate in Treatment: A Case Series Study, Dermatology Practical and Conceptual (2025)
42. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
43. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
44. Trauma-Induced Pemphigus: A Case Series of 36 Patients; [Trauma-Induzierter Pemphigus: Eine Fallserie Von 36 Patienten], JDDG - Journal of the German Society of Dermatology (2016)
45. Efficacy and Safety of Bruton's Tyrosine Kinase Inhibitors in the Treatment of Pemphigus: A Comprehensive Literature Review and Future Perspective, Heliyon (2023)
46. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
47. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
48. Impact of Rituximab on Igg and Igm Levels in Patients With Autoimmune Bullous Diseases: A Cohort Study, Archives of Dermatological Research (2025)
49. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
50. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)